as 05-30-2025 4:00pm EST
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
Founded: | 2000 | Country: | United States |
Employees: | N/A | City: | Rockville |
Market Cap: | 97.2M | IPO Year: | 2013 |
Target Price: | $5.33 | AVG Volume (30 days): | 378.7K |
Analyst Decision: | Hold | Number of Analysts: | 9 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.89 | EPS Growth: | N/A |
52 Week Low/High: | $0.99 - $5.77 | Next Earning Date: | 05-13-2025 |
Revenue: | $154,050,000 | Revenue Growth: | 255.31% |
Revenue Growth (this year): | -69.28% | Revenue Growth (next year): | 45.52% |
MGNX Breaking Stock News: Dive into MGNX Ticker-Specific Updates for Smart Investing
Zacks
9 days ago
Zacks
10 days ago
MT Newswires
12 days ago
Simply Wall St.
16 days ago
Zacks
18 days ago
Associated Press Finance
18 days ago
GlobeNewswire
18 days ago
GuruFocus.com
19 days ago
The information presented on this page, "MGNX MacroGenics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.